Ignite Creation Date:
2024-05-05 @ 9:08 PM
Last Modification Date:
2024-10-26 @ 10:00 AM
Study NCT ID:
NCT00829660
Status:
COMPLETED
Last Update Posted:
2017-07-25
First Post:
2009-01-26
Brief Title:
Acarbose Cardiovascular Evaluation Trial
Sponsor:
University of Oxford
Organization:
University of Oxford
Study Overview
Official Title:
A Long-term Multicentre Double-blind Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACE
Brief Summary:
The purpose of this study is to determine whether acarbose therapy can reduce cardiovascular-related morbidity and mortality in patients with impaired glucose tolerance IGT who have established coronary heart disease CHD or acute coronary syndrome ACS A secondary objective of the study is to determine if acarbose therapy can prevent or delay transition to type 2 diabetes mellitus T2DM in this patient population
Detailed Description:
A long-term multicentre double-blind randomised parallel-group trial to determine whether reducing post-prandial glycaemia can reduce cardiovascular-related morbidity and mortality in patients with established coronary heart disease or acute coronary syndrome who have impaired glucose tolerance
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ISRCTN91899513 | None | None | None |